Cardioprotection research must leave its comfort zone

Author:
Publisher website
Google Scholar
Abstract
The translation from mechanistic, more reductionist basic science research to clinical outcome studies is not a linear, rational process but fraught with many surprises such that the prediction of a clinically meaningful endpoint even from a robust preclinical endpoint is difficult. Such translational gap is not genuine for the field of cardioprotection, but particularly prominent here since there are literally thousands of basic science studies on cardioprotective interventions, drugs and signalling mechanisms but just one phase III trial with improved clinical outcome as primary endpoint.1 In the more robust experimental studies, cardioprotection has been evidenced as a reduction of infarct size following a protocol of transmural myocardial...
Funding Information
  • German Research Foundation (He 1320/18-3, SFB 1116 B8)
  • EU Cardioprotection (16225)

This publication has 13 references indexed in Scilit: